Abnova (Taiwan) Corporation

Taiwan Stock Exchange 4133.TW

Abnova (Taiwan) Corporation Current Liabilities for the year ending December 31, 2023: USD 2.04 M

Abnova (Taiwan) Corporation Current Liabilities is USD 2.04 M for the year ending December 31, 2023, a -14.15% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Abnova (Taiwan) Corporation Current Liabilities for the year ending December 31, 2022 was USD 2.38 M, a 4.98% change year over year.
Abnova (Taiwan) Corporation Current Liabilities for the year ending December 31, 2021 was USD 2.26 M, a -14.65% change year over year.
Abnova (Taiwan) Corporation Current Liabilities for the year ending December 31, 2020 was USD 2.65 M, a 23.34% change year over year.
Abnova (Taiwan) Corporation Current Liabilities for the year ending December 31, 2019 was USD 2.15 M, a -1.51% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Taiwan Stock Exchange: 4133.TW

Abnova (Taiwan) Corporation

CEO	Yi Huang Huang
IPO Date	Dec. 28, 2009
Location	Taiwan
Headquarters	No. 108, Jhouzih Street
Employees	110
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.

Key trends

Past 5 years